Modeling the Percutaneous Absorption of Solvent-deposited Solids Over a Wide Dose Range

Fang, Yu; Tonnis, Kevin; Xu, Lijing; Jaworska, Joanna; Kasting, Gerald B.

doi:10.1016/j.xphs.2021.10.001

Cited by 8 publications

(3 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limitations include low number of included trials on the basis of skin cancers, which could have been avoided by a search strategy targeting a population of individuals with a history of skin cancer; evaluation of AEs limited to three categories with quantitative reports, which may overestimate effect measures on AEs; and inclusion of trials conducted with topical nicotinamide, whose pharmacokinetics is still being studied in translational research. [13][14][15] Recent advances on cutaneous absorption of nicotinamide supported our decision to use eligibility criteria encompassing topical nicotinamide. Nevertheless, estimates for cutaneous and biochemical AEs were nonsignificant, as was the estimate for topical nicotinamide in skin cancer subgroup analyses.…”

Section: Discussionmentioning

confidence: 99%

“…Nicotinamide and its lipophilic analog methyl nicotinate were similarly absorbed in ex vivo human skin, and in vivo dermal delivery of nicotinamide was greater with a binary vehicle of propylene glycol and linolenic acid. [13][14][15] This systematic review and meta-analysis aimed to assess the effect of nicotinamide for skin cancer chemoprophylaxis in a large population of patients regardless of immunosuppression status.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis

2022

View full text Add to dashboard Cite

Background Oral nicotinamide is recommended in individuals with a field of cancerization or with ≥1 previous cutaneous squamous cell carcinoma (cSCC). Objective To evaluate the effect of nicotinamide in prevention of skin cancers. Methods We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of nicotinamide. We used Medline, EMBASE, CENTRAL, and Web of Science databases from their inception to October 2020 to search the following concepts: “nicotinamide”; “randomized controlled trial” (validated filters). Two independent reviewers screened titles and abstracts for intervention and study design before searching full texts for eligibility criteria. To be eligible, ≥1 outcome had to be covered. We used a standardized collection grid to complete data extraction in duplicate. The primary outcome was skin cancers (all types). Secondary outcomes were basal cell carcinomas (BCCs); cSCCs; actinic keratoses; melanomas; digestive, cutaneous, and biochemical adverse effects (AEs). Subgroup analyses were planned a priori. Results We screened 4730 citations and found 29 trials (3039 patients) meeting inclusion criteria. Nicotinamide was associated with a significant reduction in skin cancers compared to control (rate ratio 0.50 (95% CI, 0.29-0.85; I 2 = 64%; 552 patients; 5 trials); moderate strength of the evidence). Heterogeneity was explained by risk of bias. Nicotinamide was associated with a significant reduction in BCCs and cSCCs, and increased risk of digestive AEs. Conclusion Oral nicotinamide should be considered in healthy patients or organ transplant recipients with history of skin cancer (GRADE: weak recommendation; moderate-quality evidence), in particular of BCC and cSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%